CClinicalTrials.gg
Status unknownNCT05330806Updated Mar 10, 2023

Collagenase Chemonucleolysis vs Percutaneous Endoscopic Lumbar Discectomy (PELD) for Lumbar Disc Herniation

An interventional study of Collagenase chemonucleolysis and Percutaneous endoscopic lumbar discectomy (PELD) in Lumbar Disc Herniation, sponsored by Shenzhen People's Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-10.

Sponsored by Shenzhen People's Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jan 2021, registered Mar 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Lumbar disc herniation compressed the nerve cause pain, numbness, weak legs called sciatica, which seriously decrease the quality of life and work efficiency. Both collagenase chemonucleolysis(CCNL) and percutaneous endoscopic lumbar discectomy (PELD) was effective to treat lumbar disc herniation(LDH) requires surgery. whether functional clinical outcomes of CCNL vs PELD effect on LDH was superior, and no study provided convincing evidence.

Read the detailed description

Lumbar disc herniation (LDH) is a common disease with an incidence of 1%-3%, usually manifested as low back pain radiating to the lower extremities, which seriously affects patients' quality of life. Collagen hydrolysis was effective in treating LDH, it makes the protrusion smaller or disappeared, relieving or resolving the compression of nerve root by the protrusion.Percutaneous endoscopic lumbar discectomy (PELD) is a less invasive techniques to treat LDH. However, the outcomes of collagen hydrolysis vs PELD effect was still unknown.

02

Conditions studied

  • Lumbar Disc Herniation
03

In context

Intervertebral Disc Displacement

478 studies on the registry are indexed under Intervertebral Disc Displacement; 104 are open to participants now.

This study's planned enrollment of 140 is above the median of 63 across 344 interventional studies indexed under Intervertebral Disc Displacement.

Browse Intervertebral Disc Displacement studies →

Lead sponsor

Shenzhen People's Hospital is the lead sponsor of 62 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • at least six weeks of excessive radiating leg pain with no tendency for any clinical improvement despite conservative therapy
  • have a nerve root compression by a lumbar disc herniation proven by magnetic resonance imaging

Exclusion criteria

Exclusion Criteria:

  • previous surgery at the same or adjacent disc level;
  • isthmic or degenerative spondylolisthesis
  • pregnancy
  • severe comorbid medical or psychiatric disorder (American Society of Anesthesiologists' classification >2);
  • severe caudal or cranial sequestration of disc fragments, defined as sequestration towards more than half of the adjacent vertebra;
  • contraindication for surgery
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Collagenase chemonucleolysis

    After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via "safe" entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months.

    Procedure: Collagenase chemonucleolysis

  • Active comparator
    Percutaneous endoscopic lumbar discectomy (PELD)

    For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.

    Procedure: Percutaneous endoscopic lumbar discectomy (PELD)

Interventions

  • ProcedureCollagenase chemonucleolysis

    After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via "safe" entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months.

  • ProcedurePercutaneous endoscopic lumbar discectomy (PELD)

    For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.

    Also known as: Percutaneous transforaminal endoscopic discectomy (PTED) for L1-L4 and percutaneous endoscopic interlaminar discectomy(PEID) for L5-S1 lumbar disc herniation

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale/Score of leg

    Visual Analogue Scale pain assess for leg. Use a ruler about 10cm long, one side is marked with "0" and the other "10" respectively. A score of 0 indicates no pain, 10 indicates the most unbearable pain.

    Time frame: up to 12 months

  2. Visual Analogue Scale/Score of lumbar

    Visual Analogue Scale pain assess for lumbar. Use a ruler about 10cm long, one side is marked with "0" and the other "10" respectively. A score of 0 indicates no pain, 10 indicates the most unbearable pain.

    Time frame: up to 12 months

  3. Recurrence rate

    The percentage of disc herniation recurrence appearance. 0 represents the minimum and 100% represents the maximum.

    Time frame: up to 12 months

  4. reoperation

    The percentage of reoperation rate. 0 represents the minimum and 100% represents the maximum.

    Time frame: up to 12 months

Secondary outcomes

  1. The Roland-Morris Disability Questionnaire

    The Roland-Morris Disability Questionnaire is a health status measure designed to be completed by patients to assess physical disability due to low back pain. The lowest score is 0, the highest 24. The higher the score, the more severe the dysfunction.

    Time frame: up to 12 month

  2. the EuroQoL-5D (EQ-5D)

    EQ-5D descriptive system is a preference-based Health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. From this, a quality of life score can be calculated ranging from -0.594, indicating a health state worse than death where 0 is death, to 1, indicating full health

    Time frame: up to 12 month

  3. Duration of operation

    Duration of operation time: The minimum value is 1 minute, and the maximum value is 120 minutes

    Time frame: up to 12 month

  4. Length of stay in the hospital

    Length of stay in the hospital: The minimum value is 1 day. The maximum value is 30 days

    Time frame: up to 12 month

  5. Major complications

    Major complications includes cerebrospinal fluid leakage,deep venous thrombosis in the leg, transient increase in neurological deficit, repeated surgery,Opioid analgesics

    Time frame: up to 12 month

  6. hospital fees

    hospital fees :Minimum 500 yuan, maximum 30,000 yuan

    Time frame: up to 12 month

  7. the Oswestry Disability Index (ODI)

    Disability was evaluated using the Oswestry Disability Index (ODI)

    Time frame: up to 12 month

  8. the Medical Outcomes Study 12-item short-form health survey (SF-12) scale

    SF-12 including mental and physical components, was shorter versions of 36-item Short-Form Health Survey (SF-36) to evaluate life quality

    Time frame: up to 12 month

  9. modified MacNab

    modified MacNab criteria is patient satisfaction with excellent outcomes, good, fair, and poor.

    Time frame: up to 12 month

  10. cost-effectiveness

    Incremental cost-effectiveness ratios (ICERs) will be calculated by dividing the difference in costs by the difference in effects.

    Time frame: up to 12 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gibson JN, Cowie JG, Iprenburg M. Transforaminal endoscopic spinal surgery: the future 'gold standard' for discectomy? - A review. Surgeon. 2012 Oct;10(5):290-6. doi: 10.1016/j.surge.2012.05.001. Epub 2012 Jun 15. PubMed 22705355 ↗
  • Yuan P, Shi X, Wei X, Wang Z, Mu J, Zhang H. Development process and clinical application of collagenase chemonucleolysis in the treatment of lumbar disc herniation: a narrative review in China. Postgrad Med J. 2022 Mar 14:postgradmedj-2021-141208. doi: 10.1136/postgradmedj-2021-141208. Online ahead of print. PubMed 35288448 ↗
  • Gadjradj PS, Harhangi BS. Percutaneous Transforaminal Endoscopic Discectomy for Lumbar Disk Herniation. Clin Spine Surg. 2016 Nov;29(9):368-371. doi: 10.1097/BSD.0000000000000366. PubMed 26945128 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05330806
Lead sponsor
Shenzhen People's Hospital
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Jan 15, 2021
Primary completion
Jun 25, 2023 (estimated)
Completion
Jun 28, 2023 (estimated)
Last update
Mar 10, 2023

Study contacts

Hongyu Wang, Doctor
Contact
wanghongyu790039663@126.com
18241651300
Ziming Zhao, Master
Contact
zhzm622@163.com
18841609587
Songlin Peng, Doctor
principal investigator · Shenzhen People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion